Jiayuh Lin

University of Maryland, Baltimore — United States

Medicine · Health Sciences

62h-index10.3kcitations238works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(132), Cancer-related Molecular Pathways(38), Cancer Mechanisms and Therapy(34), Protein Tyrosine Phosphatases(29), PI3K/AKT/mTOR signaling in cancer(28)

Publications238 total

IL-6 Blockade Enhances the Efficacy of CDK4/6 Inhibitor in BRCA1-Mutant Triple-Negative Breast Cancer Cells
Cells·2025· 1 citedOpen Access
Zebrafish as a model system for studying cilia biology and ciliopathies
Seminars in Cell and Developmental Biology·2025
Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer
Biomolecules·2025· 2 citedOpen Access
Abstract 5724: Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer cells
Cancer Research·2025· 1 cited
Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers
Cells·2024Open Access
Correction: Regua et al. TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers 2021, 13, 2340
Cancers·2024Open Access
Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling
Current Oncology·2024· 9 citedOpen Access
Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis
Oncogene·2024Open Access
Abstract 4610: Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells
Cancer Research·2024
CDK4/6 inhibitors in lung cancer: current practice and future directions
European Respiratory Review·2024· 25 citedOpen Access
Bazedoxifene Suppresses the Growth of Osteosarcoma Cells by Inhibiting IL-6 and IL-11/GP130 Signaling Pathway
Journal of Pediatric Hematology/Oncology·2023· 2 cited
Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma
Cancers·2023· 13 citedOpen Access
Supplemental Figure Legends and Figures 1-7 from The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
2023Open Access
Supplementary Figure Legends 1-3 from Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
2023Open Access
Supplemental Figure Legends and Figures 1-7 from The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
2023Open Access
Data from Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
2023Open Access
Data from Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
2023Open Access
Supplementary Figures 1-3 from Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
2023Open Access
Data from The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
2023Open Access
Supplementary Figure Legends 1-3 from Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Chenglong Li(17), Pui‐Kai Li(15), Li Lin(11), James R. Fuchs(11), Brian Hutzen(8), Stephanie Deangelis(7), Arnold J. Levine(6), Sarah Ball(6), Melinda Huang(4), R. Kevin Reynolds(4), Elizabeth Foust(4), Matthew Sobo(4), Ling Cen(4), Chun‐Liang Chen(4), Eric Schwartz(4), Hui‐Wen Lo(4), Shaomeng Wang(3), Huey‐Jen Lin(3), Huameng Li(3), Bulbul Pandit(3)